厄他培南/齐德巴坦(WCK 6777)对问题肠杆菌目的活性
该研究采用BSAC琼脂稀释法测定厄他培南/齐德巴坦对1632株英国国家参考实验室肠杆菌目的MIC。在0.5 mg/L折点下,超过90%的产AmpC、ESBL、KPC、金属酶或OXA-48碳青霉烯酶的E. coli被抑制;动物研究支持8 mg/L折点,据此除产金属酶(±OXA-48)的K. pneumoniae/oxytoca外,各菌群90%-100%分离株对厄他培南/齐德巴坦敏感。
要点
- 厄他培南/齐德巴坦拟用于2+2 g q24h给药,适合门诊肠外抗菌治疗(OPAT)。
- 在厄他培南现行0.5 mg/L折点下,超过90%的产AmpC、ESBL、KPC、金属酶或OXA-48碳青霉烯酶的E. coli被厄他培南/齐德巴坦1:1抑制。
- 基于动物研究支持的8 mg/L折点,除产金属酶(±OXA-48)的K. pneumoniae/oxytoca外,各菌群90%-100%分离株对厄他培南/齐德巴坦敏感。
核心结论
- 厄他培南/齐德巴坦拟用每日一次方案,适合OPAT。
- 即使采用高度保守的折点预测,厄他培南/齐德巴坦对MDR E. coli(包括产金属碳青霉烯酶者)具有潜在活性。
- 若试验数据支持动物实验提示的8 mg/L折点,其潜在应用将广泛覆盖由产ESBL、AmpC和碳青霉烯酶肠杆菌目引起的感染。
研究设计与样本
- 研究采用BSAC琼脂稀释法测定MIC。
- 对1632株提交至英国国家参考实验室进行抗菌药物耐药性检测的肠杆菌目进行了MIC测定。
主要发现
- 在厄他培南现行0.5 mg/L折点下,超过90%的产AmpC、ESBL、KPC、金属酶或OXA-48碳青霉烯酶的E. coli被厄他培南/齐德巴坦1:1抑制。
- 在0.5 mg/L折点下,对其他主要肠杆菌目,厄他培南/齐德巴坦1:1抑制比例大多为65%至90%,但对产金属β-内酰胺酶或OXA-48 β-内酰胺酶的K. pneumoniae/oxytoca比例较低。
- 动物研究支持厄他培南/齐德巴坦的8 mg/L折点,依据是与厄他培南单药相比所需T>MIC缩短。
- 基于8 mg/L折点,除产金属β-内酰胺酶(±OXA-48)的K. pneumoniae/oxytoca外,厄他培南/齐德巴坦对全部菌群中90%-100%的分离株有活性。
- 产金属β-内酰胺酶(±OXA-48)的K. pneumoniae/oxytoca的MIC和敏感百分比即使接种量在BSAC可接受范围内也变化很大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 产金属β-内酰胺酶(±OXA-48)的K. pneumoniae/oxytoca的MIC和敏感百分比即使接种量在BSAC可接受范围内也变化很大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary healthcare will remain pressured for some years, both because SARS-CoV-2 will circulate as a nosocomial pathogen, and owing to backlogs of patients awaiting delayed elective procedures. These stresses will drive the use of Outpatient Parenteral Antibiotic Therapy (OPAT), which will need to cover increasingly resistant Gram-negative opportunists. We evaluated the activity of ertapenem/zidebactam, proposed for 2 + 2 g q24h administration. MATERIALS AND METHODS: MICs were determined, by BSAC agar dilution, for 1632 Enterobacterales submitted to the UK national reference laboratory for investigation of antimicrobial resistance. RESULTS: Over 90% of Escherichia coli with AmpC, ESBLs, KPC, metallo- or OXA-48 carbapenemases were inhibited by ertapenem/zidebactam 1:1 at ertapenem's current 0.5 mg/L breakpoint. For other major Enterobacterales, the proportions inhibited by ertapenem/zidebactam 1:1 at 0.5 mg/L were mostly 65% to 90% but were lower for Klebsiella pneumoniae/oxytoca with metallo- or OXA-48 β-lactamases. However, animal studies support an 8 mg/L breakpoint for ertapenem/zidebactam, based on a shortened T>MIC being needed compared with ertapenem alone. On this basis ertapenem/zidebactam would count as active against 90%-100% of isolates in all groups except K. pneumoniae/oxytoca with MBLs (±OXA-48), where MICs and percent susceptibility vary substantially even with inocula within the BSAC acceptable range. CONCLUSIONS: Ertapenem/zidebactam has a proposed once-daily regimen well suited to OPAT. Even on highly conservative breakpoint projections, it has potential against MDR E. coli, including metallo-carbapenemase producers. If trial data sustain the 8 mg/L breakpoint indicated by animal experiments, its potential will extend widely across infections due to ESBL-, AmpC- and carbapenemase-producing Enterobacterales.
引用
- Mushtaq S, Garello P, Vickers A, et al. Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales. J Antimicrob Chemother. 2022. PMID: 35972407. doi:10.1093/jac/dkac280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。